RARA fusion genes in acute promyelocytic leukemia: a review. Issue 3 (June 2014)

• Record Type: Journal Article
• Authors: De Braekeleer, Etienne; Douet-Guilbert, Nathalie; De Braekeleer, Marc
• Is Part Of: Expert review of hematology. Volume 7:Issue 3(2014)
• Page Start: 347
• Page End: 357
• Publication Date: 2014-06
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1586/17474086.2014.903794
• Languages: English
• ISSNs: 1747-4086

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>The t(15;17)(q24;q21), generating a PML-RARA fusion gene, is the hallmark of acute promyelocytic leukemia (APL). At present, eight other genes fusing with RARA have been identified. The resulting fusion proteins retain domains of the RARA protein allowing binding to retinoic acid response elements (RARE) and dimerization with the retinoid X receptor protein (RXRA). They participate in protein-protein interactions, associating with RXRA to form hetero-oligomeric complexes that can bind to RARE. They have a dominant-negative effect on wild-type RARA/RXRA transcriptional activity. Moreover, RARA fusion proteins can homodimerize, conferring the ability to regulate an expanded repertoire of genes normally not affected by RARA. RARA fusion proteins behave as potent transcriptional repressors of retinoic acid signalling, inducing a differentiation blockage at the promyelocyte stage which can be overcome with therapeutic doses of ATRA or arsenic trioxide. However, resistance to these two drugs is a major problem, which necessitates development of new therapies.</p> </abstract>